explore -WSS

explore

author：fashion 2025-10-01 21:33:22 - browse：235

Pfizer on Friday said it was stopping development of a twice-daily oral obesity medication after an underwhelming clinical trial, a blow to the company’s efforts to compete in the booming field of weight-loss medications.

The medicine, danuglipron, met its primary target in a placebo-controlled Phase 2b trial, leading to a statistically significant amount of weight lost, the company said. But the weight reductions were smaller than those seen in trials of rival medicines targeting the same GLP-1 pathway, and a high rate of patients experienced side effects and dropped out of the trial.

Pfizer said it would not move twice-daily danuglipron into Phase 3 trials, but that instead it would focus on a once-daily formulation, which is currently undergoing pharmacokinetic studies. Data are expected in the first half of 2024.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Tori Bowie and the unacceptable rates of Black maternal death
Next article： To spot an incipient stroke, tiny brain probe acts ‘like a microscope’

WSS

Readout Newsletter: Raw milk, Wegovy tests, Eisai and Biogen

Judge sides with young activists in first

Indictment alleges Trump's ex

Readout Newsletter: Raw milk, Wegovy tests, Eisai and Biogen

Aspartame and sugar

WuXi Biologics execs register to lobby as Congress comes for the company

knowledge

explore

Wikipedia

Trump demands the U.S. pay no more for drugs than other countries … again

Patients, digital health players weigh in on FTC's data privacy plan

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

YouTube cracks down on misinformation on cancer treatment

BioMarin wins approval for gene therapy to treat hemophilia A

To spot an incipient stroke, tiny brain probe acts ‘like a microscope’

Walensky prepares to leave CDC — and Congress — behind

What a koala virus tells us about the human genome

Bright Health sells Medicare Advantage business to Molina

Dozens dead from Maui wildfires: What we know about the victims

knowledge

Aspartame and sugar

Oak Street deal isn't the answer to health care's woes

Ripples from Flovent's discontinuation is killing children with asthma

Timeline: How the deadly wildfires took over Maui day by day

Cherokee Nation medical school graduates its first class

Schizophrenia gene found to be linked to cells' energy dysfunction

explore

knowledge

entertainment

knowledge